Evaluation of the Safety and Thrombolytic Effects of Ascending Doses of TS23 in Subjects With Intermediate-Risk (Sub-Massive) Acute Pulmonary Embolism
Latest Information Update: 06 Jul 2026
At a glance
- Drugs TS 23 (Primary)
- Indications Pulmonary embolism
- Focus Adverse reactions; Therapeutic Use
- Acronyms NAIL-IT
- Sponsors Translational Sciences
Most Recent Events
- 06 Jul 2026 Planned number of patients changed from 32 to 64.
- 01 Jul 2026 Planned End Date changed from 1 Sep 2024 to 1 Nov 2026.
- 01 Jul 2026 Planned primary completion date changed from 1 Jul 2024 to 31 Aug 2026.